Investing.com - Financial Markets Worldwide
💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

U.S. CDC backs full approval of Moderna's COVID-19 vaccine

Published 02/04/2022, 05:13 PM
Updated 02/04/2022, 05:21 PM
© Reuters. FILE PHOTO: A healthcare worker prepares a syringe with the Moderna COVID-19 vaccine at a pop-up vaccination site operated by SOMOS Community Care during the COVID-19 pandemic in Manhattan in New York City, New York, U.S., January 29, 2021. REUTERS/Mike S
MRNA
-

(Reuters) - The director of the U.S. Centers for Disease Control and Prevention (CDC) signed off on the U.S. Food and Drug Administration's full approval of Moderna (NASDAQ:MRNA) Inc's COVID-19 vaccine in those aged 18 and over, the agency said on Friday.

The vaccine has been in use under the U.S Food and Drug Administration's emergency use authorization since December 2020, and is now the second fully approved vaccine for COVID-19 in the United States.

Earlier on Friday, a CDC panel voted unanimously to recommend the vaccine's use, after the FDA granted full approval of the shot on Monday.

While the FDA approves vaccines, the CDC needs to sign off on how they will be implemented in the United States. CDC Director Rochelle Walensky's green light is the final formality of the approval process.

The vaccine will now be sold under the brand name as Spikevax.

© Reuters. FILE PHOTO: A healthcare worker prepares a syringe with the Moderna COVID-19 vaccine at a pop-up vaccination site operated by SOMOS Community Care during the COVID-19 pandemic in Manhattan in New York City, New York, U.S., January 29, 2021. REUTERS/Mike Segar

The COVID-19 vaccine from Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) received full approval for those aged 16 and over in August.

Roughly 75 million people in the United States have been fully-vaccinated with Moderna's shot.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.